Cite
Pol JG, Acuna SA, Yadollahi B, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2018;8(1):e1512329doi: 10.1080/2162402X.2018.1512329.
Pol, J. G., Acuna, S. A., Yadollahi, B., Tang, N., Stephenson, K. B., Atherton, M. J., Hanwell, D., El-Warrak, A., Goldstein, A., Moloo, B., Turner, P. V., Lopez, R., LaFrance, S., Evelegh, C., Denisova, G., Parsons, R., Millar, J., Stoll, G., Martin, C. G., Pomoransky, J., Breitbach, C. J., Bramson, J. L., Bell, J. C., Wan, Y., Stojdl, D. F., Lichty, B. D., & McCart, J. A. (2019). Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology, 8(1), e1512329. https://doi.org/10.1080/2162402X.2018.1512329
Pol, Jonathan G, et al. "Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials." Oncoimmunology vol. 8,1 (2019): e1512329. doi: https://doi.org/10.1080/2162402X.2018.1512329
Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019. PMID: 30546947; PMCID: PMC6287790.
Copy
Download .nbib